EU agency backs new use of Bayer's drug Zevalin
LONDON, March 20 (Reuters) - The European Medicines Agency said on Thursday it had recommended approval of Bayer's (BAYG.DE) cancer drug Zevalin in treating follicular lymphoma.
The medicine is currently authorised for patients with follicular B-cell non-Hodgkin's lymphoma, in combination with rituximab.
Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months. (Reporting by Ben Hirschler)
© Thomson Reuters 2009 All rights reserved
Citadel enters the fray
Kenneth Griffin's powerful hedge fund has waded into the case of Goldman Sachs' purloined computer code, suing three of its former employees for setting up Teza Technologies. Full Article | Full Coverage
